Bioxcel Therapeutics ((BTAI)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: BioXcel Therapeutics is conducting a study titled ‘Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder.’ The study aims to evaluate the effectiveness of patient and informant-assessed outcome measures in determining the severity of psychomotor agitation episodes in individuals with Bipolar Disorders, Schizophrenia, and related conditions, and to compare these with clinician assessments.
Intervention/Treatment: The study tests BXCL501, a sublingual film containing 120 mcg of Dexmedetomidine, designed to manage acute psychomotor agitation in patients.
Study Design: This is an open-label, Phase 2 interventional study with a single-group model. It focuses on treatment, with no masking involved, to assess the agreement between different raters’ evaluations.
Study Timeline: The study began on June 19, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on August 8, 2025, indicating ongoing recruitment.
Market Implications: The progress of this study could significantly influence BioXcel Therapeutics’ stock performance, as positive results may enhance investor confidence and market positioning. The study’s outcomes could also impact the competitive landscape in the treatment of psychomotor agitation, affecting similar companies in the industry.
The study is currently ongoing, with further details available on the ClinicalTrials portal.